RegenxBio, Adaptimmune, Calithera price follow-ons

RegenxBio Inc. (NASDAQ:RGNX), Adaptimmune Therapeutics plc (NASDAQ:ADAP) and Calithera Biosciences Inc. (NASDAQ:CALA) each priced follow-on offerings, raising a total of $206 million.

Gene therapy play RegenxBio raised $75.9 million through the sale of 3.7 million shares at $20.50 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Piper Jaffray and Chardan. The price is a 3% discount to RegenxBio's close of $21.10 on Tuesday, when it proposed and priced the offering after market hours. The company lost $1.65 to $20.45 on Wednesday...